-
Since results of the 2002 Women's Health Initiative (WHI) report suggested that use of menopausal hormone therapy increases risk of coronary heart disease, science has examined the timing of therapy initiation on safe use of such treatment.
-
Four hundred thousand (1.6% of U.S. adolescents) experience serious physical and/or sexual dating violence each year.
-
Trichomoniasis is the most common curable sexually transmitted infection (STI) in young, sexually active women, according to the Centers for Disease Control and Prevention. An estimated 7.4 million new cases occur each year in U.S. women and men.
-
Amphora, under development by Evofem of San Diego, is a bioadhesive acid-buffering gel that coats the vaginal wall and cervix. Amphora helps maintain a woman's natural pH level between 3.8 and 4.2.
-
When HIV is not diagnosed until women go into labor, their infants usually are treated soon after birth with the antiretroviral drug zidovudine to prevent infant infection.
-
-
In this issue: Anticholinergic drugs for COPD; pioglitazone for diabetes prevention; insulin degludec in Phase 3 trials; and FDA Actions.
-
Among 701 women with chronic pelvic pain (CPP), 22% were affected by clinical depression. After undergoing either surgery (including hysterectomy) or non-surgical alternatives, response to the therapy was found to be independent of the presence of depression.
-
The investigators prospectively enrolled and followed a cohort of 97 teenagers before, and 6, 12, and 18 months after starting depot medroxyprogesterone acetate (DMPA).
-
Endometriosis is a common disorder in reproductive-age women and has been associated with an increased risk for development of invasive ovarian cancer.